Group B Streptococcus in surgical site and non-invasive bacterial infections worldwide: A systematic review and meta-analysis.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 27 03 2019
revised: 15 04 2019
accepted: 18 04 2019
pubmed: 28 4 2019
medline: 1 8 2019
entrez: 28 4 2019
Statut: ppublish

Résumé

The epidemiology of disease caused by group B Streptococcus (GBS; Streptococcus agalactiae) outside pregnancy and the neonatal period is poorly characterized. The aim of this study was to quantify the role of GBS as a cause of surgical site and non-invasive infections at all ages. A systematic review (PROSPERO CRD42017068914) and meta-analysis of GBS as a proportion (%) of bacterial isolates from surgical site infection (SSI), skin/soft tissue infection (SSTI), urinary tract infection (UTI), and respiratory tract infection (RTI) was conducted. Seventy-four studies and data sources were included, covering 67 countries. In orthopaedic surgery, GBS accounted for 0.37% (95% confidence interval (CI) 0.08-1.68%), 0.87% (95% CI 0.33-2.28%), and 1.46% (95% CI 0.49-4.29%) of superficial, deep, and organ/space SSI, respectively. GBS played a more significant role as a cause of post-caesarean section SSI, detected in 2.92% (95% CI 1.51-5.55%), 1.93% (95% CI 0.97-3.81%), and 9.69% (95% CI 6.72-13.8%) of superficial, deep, and organ/space SSI. Of the SSTI isolates, 1.89% (95% CI 1.16-3.05%) were GBS. The prevalence of GBS in community and hospital UTI isolates was 1.61% (1.13-2.30%) and 0.73% (0.43-1.23%), respectively. GBS was uncommonly associated with RTI, accounting for 0.35% (95% CI 0.19-0.63%) of community and 0.27% (95% CI 0.15-0.48%) of hospital RTI isolates. GBS is implicated in a small proportion of surgical site and non-invasive infections, but a substantial proportion of invasive SSI post-caesarean section.

Identifiants

pubmed: 31028879
pii: S1201-9712(19)30187-0
doi: 10.1016/j.ijid.2019.04.017
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Pagination

116-129

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Simon M Collin (SM)

Healthcare-Associated Infection and Antimicrobial Resistance (HCAI & AMR) Division, National Infection Service, Public Health England, London, UK. Electronic address: simon.collin@phe.gov.uk.

Nandini Shetty (N)

Healthcare-Associated Infection and Antimicrobial Resistance (HCAI & AMR) Division, National Infection Service, Public Health England, London, UK.

Rebecca Guy (R)

Healthcare-Associated Infection and Antimicrobial Resistance (HCAI & AMR) Division, National Infection Service, Public Health England, London, UK.

Victoria N Nyaga (VN)

SCIENSANO, Unit of Cancer Epidemiology, Belgian Cancer Centre, Brussels, Belgium.

Ann Bull (A)

VICNISS Coordinating Centre, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Michael J Richards (MJ)

VICNISS Coordinating Centre, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Tjallie I I van der Kooi (TII)

Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Mayke B G Koek (MBG)

Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Mary De Almeida (M)

Microbiology Department, LabPlus, Auckland District Health Board, Auckland, New Zealand.

Sally A Roberts (SA)

Microbiology Department, LabPlus, Auckland District Health Board, Auckland, New Zealand.

Theresa Lamagni (T)

Healthcare-Associated Infection and Antimicrobial Resistance (HCAI & AMR) Division, National Infection Service, Public Health England, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH